Breaking
INTLMidtown Manhattan Building Evacuated After Steel Beams BendARفيفا ترفض طلب فرنسا إلغاء بطاقة أوليسي الصفراء قبل مواجهة المغربITWimbledon: Sinner in semifinale contro Djokovic, eliminati Paolini e CobolliUSPrime Intellect Raises $130 Million Series A for AI Agent Development PlatformINGiant Southeast Asian Trees Have Evolved Specialized Water Transport SystemsTRBeşiktaş'tan Alexander Nübel transferi için resmi açıklamaARوفاة رجل خلال احتفالات كأس العالم في الأرجنتين.. وقرارات سياسية تمنع حكام إنجليز من إدارة مباريات الأرجنتينBRPesquisa revela grande variação de preços em medicamentos no BrasilINTLViral Video Falsely Claimed to Show Iran Attack on US FacilityDETrump verteidigt Vorgehen gegen Iran nach Nato-GipfelINTLMidtown Manhattan Building Evacuated After Steel Beams BendARفيفا ترفض طلب فرنسا إلغاء بطاقة أوليسي الصفراء قبل مواجهة المغربITWimbledon: Sinner in semifinale contro Djokovic, eliminati Paolini e CobolliUSPrime Intellect Raises $130 Million Series A for AI Agent Development PlatformINGiant Southeast Asian Trees Have Evolved Specialized Water Transport SystemsTRBeşiktaş'tan Alexander Nübel transferi için resmi açıklamaARوفاة رجل خلال احتفالات كأس العالم في الأرجنتين.. وقرارات سياسية تمنع حكام إنجليز من إدارة مباريات الأرجنتينBRPesquisa revela grande variação de preços em medicamentos no BrasilINTLViral Video Falsely Claimed to Show Iran Attack on US FacilityDETrump verteidigt Vorgehen gegen Iran nach Nato-Gipfel
Newsgather
BackChinese Researchers Claim Lead in Parkinson's Stem Cell Therapy
Chinese Researchers Claim Lead in Parkinson's Stem Cell Therapy
Health
SCMP News5/20/2026Health1 min readChina

Chinese Researchers Claim Lead in Parkinson's Stem Cell Therapy

Quick Look

Chinese company Nuwacell claims its stem cell therapy for Parkinson's disease shows significantly higher efficiency (80-90% conversion) than international competitors (below 25%), citing faster clinical trial timelines.

AI-generated summary

Why It Matters

Parkinson's disease is a movement disorder caused by a lack of dopamine due to the death or dysfunction of specialized neurons. Stem cell therapies are being explored globally to replenish these lost neurons. Nuwacell Biotechnologies, founded by scientists returning from the US, claims to be leading this field.

Font size

Chinese researchers claim to be outpacing international competitors in the development of stem cell therapies for Parkinson’s disease, citing higher efficiency and a faster clinical trial timeline.

Parkinson’s is often described as a movement disorder. Its symptoms are caused by the brain’s failure to produce sufficient dopamine, because of the death or dysfunction of the specialised neurons responsible for generating the chemical.

In the search for a cure, researchers around the world are exploring stem cell therapies aimed at replenishing lost dopaminergic neurons – a field in which one Chinese company is claiming to be taking the lead.

Nuwacell Biotechnologies was founded a decade ago in Hefei, Anhui province, by stem cell biologists Yu Junying and Zhang Ying upon their return to China from leading US institutions.

Speaking to the South China Morning Post after an academic exchange conference in Beijing, Yu – the company’s chief scientist – said Nuwacell’s therapy was showing “significantly higher efficiency” than rival international teams from the US and Japan.

“Our cells, once introduced into the body, convert into dopaminergic neurons at a rate of 80 to 90 per cent, whereas published data from other teams are below 25 per cent,” she said.

Open Questions

  • What are the specific timelines for Nuwacell's clinical trials?
  • What are the names of the leading US and Japanese institutions developing rival therapies?
  • What are the potential side effects or risks associated with Nuwacell's therapy?
  • Has Nuwacell's therapy been independently verified by other research bodies?

Related Topics

This article was originally published by SCMP News.

Related Stories

More on this topicparkinson's disease